Among the existing ADCs, only a few have shown promising efficacy in target-enriched patients, such as an ORR of 55% for T-DM1 and T-DXd in treating advanced HER2-mutated NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.